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Edited by Ned ManteiAbstract Tyrosine hydroxylase immunohistochemical analysis
revealed that in cultured mesencephalic dopaminergic neurons
smilagenin (SMI), added prior to 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPP+), protected against the drop of neu-
ron number and neurite outgrowth length caused by MPP+.
Addition of anti-GDNF and/or anti-GFRa1 functional antibod-
ies to the medium prior to SMI, eliminated mostly, though
incompletely, the action of SMI. The expression of glial cell de-
rived neurotrophic factor (GDNF) mRNA, but not GDNF recep-
tor alpha1 (GFRa1) or receptor tyrosine kinase mRNA in
MPP+ intoxicated neurons was markedly elevated as early as
2 h after the addition of SMI with a peak at 24–48 h. Therefore,
an important route of the protective action of SMI on dopami-
nergic neurons is to stimulate intrinsic GDNF expression.
 2008 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Parkinsons disease is a neuro-degenerative disorder charac-
terized by progressive loss of dopaminergic neurons in the
substantia nigra accompanied by a signiﬁcant reduction
of tyrosine hydroxylase (TH) resulting in poor production
of DOPA. The eﬀect of current treatments for Parkinsons
disease is mostly palliative and may gradually decrease after
prolonged usage or cause side eﬀects such as dyskinesia [1,2].
New therapeutic approaches aiming at delaying or even revers-
ing the degeneration of dopaminergic neurons are under active
investigation [2–5].
One important approach is to trigger endogenous neuro-
protective mechanisms, such as the brain derived and glial cell
derived neurotrophic factors (BDNF and GDNF) [6,7]. How-Abbreviations: SMI, smilagenin; GDNF, glial cell derived neurotrophic
factor; GFRa1, GDNF receptor alpha1; Ret, receptor tyrosine kinase;
TH, tyrosine hydroxylase; MPP+, 1-methyl-4-phenyl-1,2,3,6-tetrahy-
dropyridine
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doi:10.1016/j.febslet.2008.02.039ever, neurotrophic factors must be given by intracranial infu-
sion to reach the target area. Diﬀerent approaches have been
suggested to overcome this obstacle. One is to graft cell vectors
that release trophic molecules, but the immunological and eth-
ical problems remain to be overcome. Other studies try to seek
drugs that can increase intrinsic GDNF in brain. In this
regard, the presently known compounds are selegiline and
rasagiline [8]. Yet their main action is to inhibit the mono-
amine oxidase B, further study is required to evaluate the dis-
ease modifying prospects [2]. Other active components of plant
origin such as the ginsenosides [9] and the iridoid catalpol [10]
have been reported to have protective eﬀect against dopami-
nergic neuron injuries, but whether these actions are linked
to neurotrophic factors is unclear.
Smilagenin (5b,20a,22a,25R-spirostan-3b-ol, abbreviated as
SMI in this paper) is a sapogenin from Rhizoma anemarrhenae
and Radix asparagi both are medicinal herbs frequently used in
traditional Chinese medicine for treating chronic neurological
diseases. Recently, we have carried out experiments to study
the action of SMI on primary cultures of rat embryonic mes-
encephalic neurons. Data will be presented in this paper to
demonstrate that SMI can protect the cultured neurons from
the toxic eﬀect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyri-
dine (MPP+) and that the eﬀect is closely related to the stimu-
lation of GDNF mRNA expression by SMI.2. Materials and methods
2.1. Reagents
MPP+ and poly-D-lysine were from Sigma. Anti-Tyrosine hydroxy-
lase (TH) antibody, secondary biotin labeled antibody, ABC (avidin
biotin complex) kit and DAB (diaminobenzidine) were from Chem-
icon. DMEM/F12 and N2 (culture supplement) were from GIBCO.
Oligo dT12-18, RNAguard, reverse transcriptase, Taq polymerase
and GDNF ELISA kit were from Promega. The SYBR Green 1
dye kit was from Applied Biosystems. Anti-GDNF (MAB212) and
anti-GFRa1 (MAB560) functional blocking antibody were from
R&G. Smilagenin (purity 98%) used in this study was supplied by
Sigma, the structure was conﬁrmed by MS and 13C NMR.2.2. Primary culture of mesencephalic cells
Sprague–Dawley (SD) pregnant rats were obtained from Shanghai
SIPPR-BK Laboratory Animal Company. The animal experiments
were carried out in accordance with the National Institute of Health
Guide for the Care and Use of Laboratory Animals (NIH Publications
No. 80-23), revised in 1996, and were approved by the Animal Ethics
Committee of Shanghai Jiaotong University Medical School. The
culture method of mesencephalic cells was modiﬁed from Radadblished by Elsevier B.V. All rights reserved.
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of rat embryos (14–15 days) were dispersed by trypsin digestion and
trituration. After centrifugation, the cells were re-suspended in
DMEM/F12 containing 10% fetal calf serum, seeded on poly-D-
lysine-coated plates at 1 · 105cells/cm2 and cultured at 37 C in 5%
CO2. The medium was changed to DMEM/F12 plus 1% N2 on the
4th day and was then renewed every 3–4 days.
2.3. Time schedule of treatment
In order to study the preventive eﬀect of SMI against MPP+ toxicity,
the treatment schedule was to apply SMI prior to MPP+ (Fig. 1A). The
time of MPP+ action was set at 48 h because the MPP+ damage is a
complex cascade and 48 h is needed to achieve the full manifestation
of its toxicity [11,12]. The application of SMI was set at 105 M and
96 h for most experiments since preliminary experiment showed that
this dose schedule was most eﬀective against MPP+ damage. GDNF
blocking was achieved by adding functional blocking antibodies
against GDNF or/and GDNF receptor alpha1 (GFRa1) [13,14] (con-
centrations chosen according to the users guide of the manufacturer)
2 h prior to the addition of SMI/DMSO.
However, for studying the eﬀect of SMI on mRNAs of GDNF and
its receptor, the time schedule was changed to Fig. 1B. This is because
we need to study the early events after the application of SMI and yet
keep similar MPP+ damage.
2.4. TH immunohistochemistry
The method was modiﬁed from Brouard et al. [15]. In brief, cells
were ﬁxed in plate wells with 4% paraformaldehyde, treated with
0.5% H2O2, followed by sequential incubation with 0.4% Triton X-
100, 0.5% BSA at room temperature, rabbit anti-TH serum (1:200)
at 4 C and sheep anti-rabbit IgG antibody (1:200) at 37 C. The cells
were ﬁnally colour-developed with the ABC reagent and 0.03% H2O2-
DAB and were examined with an inverted microscope (Nikon
DXM1200).
2.5. GDNF ELISA
The media from 3 to 4 wells of SMI or DMSO treated cultures were
combined to make up one sample on the 9th day and concentrated 10-
fold by freeze-drying. The GDNF concentration was determined with
the GDNF Emax Immunoassay System (Promega) according to the
users guide of the assay kit.Anti-GDNF (5μg/ml) or
Anti-GFRα1(10μg/ml) (optional)
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Fig. 1. Time schedule of addition of reagents and drugs, and analysis.
(A) The time schedule for the determination of TH-positive neuron
number, neurite outgrowth length, GDNF content in culture medium
and for testing the blocking eﬀect of anti-GDNF and anti-GFRa1
antibodies. (B) The time schedule for measuring mRNA of GDNF or
its receptor. The contents of all reagents are indicated as ﬁnal
concentrations. SMI was dissolved in DMSO before addition.2.6. RT-PCR of GDNF mRNA, GFRa1 mRNA and receptor tyrosine
kinase (Ret) mRNA
The GDNF receptor is composed of the ligand binding component
GFRa1 and the receptor tyrosine kinase component Ret. In order to
test the eﬀects of MPP+ and SMI on the expression of GDNF receptor,
it is worthwhile to measure the mRNAs of both GFRa1 and Ret.
The primers of the following sequences were synthesized by Shang-
hai Shenggong Co.:GDNF Forward: 5 0-ATGAAGTTATGGGATGTC-
GTG-30Reverse: 5 0-ACCGTTTAGCGGAATGCT-
TTC-3 0GFRa1 Forward: 50-CAGGCAGTTCTTCGA-
CAAGGTT-3 0Reverse: 5 0-TGGGCCTCTCTCGTTCTTCA-3 0Ret Forward: 50-GCGCCCCGAGTGTGAGGAA-
TGTGG-3 0Reverse: 5 0-GCTGATGCAATGGGCGGCT-
TGTGC-3 0b-actin Forward: 5 0-TGTCACCAACTGGGACGATA-3 0Reverse: 5 0-TCTCAGCTGTGGTGGTGAAG-3 0Total RNA was extracted by the method of Chomczynski and Sac-
chi [16]. Semi-quantitative RT-PCR was modiﬁed from Steel and
Buckley [17]. In brief, cDNA reverse-transcribed from 250 ng of total
RNA was ampliﬁed in PCR buﬀer containing primers and Taq poly-
merase in an Amplitron II thermocycler. The cycling condition was
95 C 5 min, 37 cycles of 95 C 30 s, 57 C 30 s and 72 C 30 s, followed
by 72 C for 5 min. The electrophoretic bands were analyzed with an
image analyzer (Biorad Discovery Gel-Doc 2000).
For the Real time quantitative RT-PCR, ampliﬁcation and calcula-
tion were carried out according to the users guide of the SYBR
Green PCR Master Mix kit. In brief, the reaction mixture contained
the SYBR Green PCR Master Mix plus primers, and cDNA re-
verse-transcribed from 250 ng of total RNA. Ampliﬁcation was carried
out in an ABI Prisma 7000 Sequence Detection System. The relative
mRNA quantities of samples were automatically calculated by the
computer from the calibration curve obtained from a ‘‘reference’’
cDNA run in parallel with the samples.
Data were ﬁnally normalized by respective b-actin values from the
same run and expressed as percent of the 10 min DMSO treated
sample.3. Results
3.1. Toxicity of MPP+ on TH immunoreactive neuron number
and neurite outgrowth length and the eﬀect of SMI
Cells were treated according to time schedule of Fig. 1A
without functional antibody. Three groups were involved in
this experiment: DMSO control, DMSO +MPP+ and the
DMSO +MPP+ + SMI. TH immunohistochemistry revealed
that the number of TH-positive neurons and the length of neu-
rite outgrowth dropped markedly in the MPP+ treated samples
while SMI showed a signiﬁcant protective eﬀect (Fig. 2A–C).
Quantiﬁcation revealed that the neuron number and neurite
outgrowth length dropped signiﬁcantly to 34% and 38% in
the DMSO +MPP+ group (taking the DMSO group as
100%) and was raised to 57% and 62% in the SMI-treated
group. The protective eﬀect of SMI, though very signiﬁcant,
was incomplete.
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Fig. 2. The eﬀect of SMI on TH-positive neurons and their neurite outgrowth in primary cultures of mesencephalic neurons. (A–C) are images at
·200 magniﬁcation, scale bar represents 50 lm. Statistical results are shown in (D) and (E). The number of neurons per ﬁeld for each sample was the
average of 10 randomly selected microscopic ﬁelds. The neurite length for each sample was the average of the longest neurite of randomly selected 120
neurons, excluding the neurons having connections with other neurons or having neurites ending outside the optic ﬁeld. The neurite length was
measured by the ‘‘segmented line selection’’ of Image J software so that it was actually the sum of many segments. Means ± S.E.M. of the neuron
numbers and neurite outgrowth lengths of each group were then calculated and converted to relative amount (taking the mean of DMSO control as
100%), n = 6. * and ** indicate P < 0.05 and P < 0.01 by ANOVA followed by Newman Keuls tests. The numerals in the ﬁgure indicate the means of
relative amount of each group.
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Fig. 3 shows that the protective eﬀect of SMI was signiﬁ-
cantly blocked by anti-GDNF or anti-GFRa1 functional anti-
body applied either separately or in combination (shown in the
left, middle and right sets of columns, respectively, in Fig. 3E103 106106
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Fig. 3. The blocking eﬀect of anti-GDNF or/and anti-GFRa1 functional ant
TH-positive neurons. Treatments (the reagents added) are shown under eac
Fig. 2A. Image of double antibodies is not shown (similar to single antibod
relative values was similar to Fig. 2 but here the mean of the DMSO +MPP+
are expressed as means ± S.E.M., n = 6 for anti-GDNF group, 4 for anti-G
P < 0.05 and P < 0.01, N.S. indicates diﬀerence not signiﬁcant (ANOVA foll
means of the relative amount for each group.and F). Each set contained four groups, DMSO +MPP+,
DMSO +MPP+ + antibody, DMSO +MPP+ + SMI and
DMSO +MPP+ + SMI + antibody. Taking the average of
the ﬁrst group (DMSO +MPP+ without antibody) as 100%
(dotted horizontal line in Fig. 3E and F), the neuron number101 103106
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Y. Zhang et al. / FEBS Letters 582 (2008) 956–960 959and neurite outgrowth length were both nearly doubled by
SMI (black columns, 171–200% and 194–196%, respectively).
Anti-GDNF antibody or anti-GFRa1 antibodies signiﬁ-
cantly depressed the eﬀect of SMI (gray columns, 136–145%
and 120–133%, respectively) but showed no eﬀect on the
DMSO +MPP+ group (white column).
The suppressive eﬀect of antibodies on the action of SMI
was signiﬁcant but incomplete, even when the two antibodies
were applied together (gray columns of the right set in
Fig. 3E and F). In addition, the diﬀerence between the
SMI + antibody groups and the DMSO + antibody groups
was not signiﬁcant for neurite outgrowth length (Fig. 3F),
but remained signiﬁcant for neuron number (Fig. 3E).10min 2h 24h 48h 72h
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3.3. Eﬀect of SMI on GDNF content in culture medium
measured by ELISA
The GDNF content in culture medium was very low and
could only be detected by combining 3–4 wells and concentrat-
ing 10-fold. The resulting content of GDNF in the concentrated
medium were 2.7 ± 0.5 and 6.6 ± 0.7 pg/ml, respectively, for
DMSO and SMI-treated groups (P < 0.01 by Students t-test).
Since most of the measured values were below the smallest cal-
ibration dose, these values represent only semi-quantitative
estimations.0
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Fig. 4. RT-PCR analysis of the eﬀect of SMI on the mRNAs encoding
GDNF, GFRa1 and Ret. All samples in this experiment were pre-
treated with MPP+ for 48 h. (A) shows the electrophoretic bands
obtained from semi-quantitative RT-PCR. Times after the addition of
SMI + DMSO (+) or DMSO alone () are indicated on the top. (B–D)
are statistical results of quantitative RT-PCR of the GDNF, GFRa1,
and Ret mRNAs, respectively. The relative amounts of mRNAs were
expressed as percent of the sample treated with DMSO for 10 min of
the same run. Data are expressed as means ± S.E.M., n = 3. * and **
indicate P < 0.05 and P < 0.01 between SMI-treated and DMSO
treated groups (Students t-test).3.4. Eﬀect of SMI on mRNA levels for GDNF and GDNF
receptor in cultured mesencephalic neurons
For this experiment, since we need to observe the early
events after SMI addition, the time schedule of treatment
shown in Fig. 1B was followed. Semi-quantitative RT-PCR
(Fig. 4A) revealed that when SMI/DMSO was added 48 h after
MPP+ treatment, the GDNF mRNA content in mesencephalic
cells was rapidly and markedly elevated by SMI but not by
DMSO. The peak value appeared at 24–48 h. Statistical data
from quantitative RT-PCR showed that the SMI-treated
group was higher than vehicle treated group as early as 2 h
after treatment and the peak value was about 30 times that
seen in the DMSO treated cells (Fig. 4B).
In contrast, quantitative RT-PCR revealed that the mRNA
levels for both the ligand binding component GFRa1 and the
receptor tyrosine kinase component Ret remained at low levels
throughout (Fig. 4C and D).4. Discussion
It is generally agreed that under the action of MPP+, the TH
activity decreases signiﬁcantly accompanied by decreased TH-
positive cell number, shortened neurite outgrowth length, and
declined interneuron connections [18,19]. The selected MPP+
dose in our experiment was 2 lM (ﬁnal) which was slightly lar-
ger than the EC50 (<1 lM) [20]. TH-positive neuron number
and average neurite outgrowth were 34% and 38% of control
after 48 h of MPP+ treatment, and became 57% and 62%,
respectively, if the cells were pre-treated with 105 M SMI.
These results clearly demonstrate that SMI has a marked pro-
tective action against the damage of dopaminergic neurons by
MPP+.
It is well documented that GDNF has a protective eﬀect on
the degeneration of dopaminergic neurons. We found that if
GDNF functional blocking antibody was added 2 h prior toapplication of SMI to neutralize intrinsic GDNF [13] or
GFRa1 functional blocking antibody was added to prevent
the binding of GDNF to the respective receptor [14], the pro-
tective eﬀect of SMI was mostly eliminated. This would imply
that the protective action of SMI is achieved at least partly
through the participation of GDNF.
The ELISA results suggested that SMI treatment could ele-
vate the GDNF content in the culture medium. Unfortunately,
the assay kit was not sensitive enough for this purpose hence
the results were only a rough suggestion.
In order to obtain the time course of the GDNF mRNA lev-
els after the addition of SMI, SMI/DMSO was added after
MPP+ had acted for 48 h. Both the semi-quantitative RT-
PCR and the quantitative RT-PCR showed that SMI addition
led to a rapid increase in the GDNF mRNA. As early as 2 h
after SMI addition, GDNF mRNA was signiﬁcantly higher
than the basal level and reached a peak as high as 20–30-fold
at 24–48 h. In contrast, the GFRa1 and Ret mRNA remained
960 Y. Zhang et al. / FEBS Letters 582 (2008) 956–960unchanged. This result clearly demonstrates that the elevation
of GDNF mRNA is an early event in the action of SMI and
hence appears to be an important mechanism of its neuro-pro-
tective action.
It has been reported that extrinsic GDNF could alleviate the
degeneration of dopaminergic neurons when administered
either before or after injury [21,22]. The above result on
GDNF mRNA was obtained by adding SMI after MPP+.
Therefore, it is possible that SMI could not only prevent but
also repair the degeneration of dopaminergic neurons through
stimulating the intrinsic GDNF secretion. However, further
experiments are required to conﬁrm this.
Our data also revealed that addition of functional antibodies
could only incompletely block the eﬀect of SMI on the eleva-
tion of neuron number. Therefore it is probable that some
other factors may play a role in the eﬀect of SMI on TH-posi-
tive neurons. One possible factor is the brain derived neurotro-
phic factor (BDNF) which has been reported to have a
protective eﬀect against the damage of dopaminergic neurons
by various injurious factors [6,23]. Whether BDNF was in-
volved in the action of SMI remains to be studied. On the
other hand, as shown in Fig. 3F, the eﬀect of SMI on the neu-
rite outgrowth length but not the TH-positive neuron numbers
was nearly completely blocked by antibodies. One probable
reason is that the protective action of GDNF on doparminer-
gic neurons was more potent on the volume of cell soma and
length of neurite outgrowth than on the neuron number
[21,22].
Taken together, we have shown that SMI has a signiﬁcant
neuro-protective eﬀect on primary cultured dopaminergic neu-
rons. One important route of this action is to stimulate the
intrinsic GDNF expression.
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